CN111565742B - 使用axl诱骗受体治疗转移性癌症的方法 - Google Patents

使用axl诱骗受体治疗转移性癌症的方法 Download PDF

Info

Publication number
CN111565742B
CN111565742B CN201880084046.2A CN201880084046A CN111565742B CN 111565742 B CN111565742 B CN 111565742B CN 201880084046 A CN201880084046 A CN 201880084046A CN 111565742 B CN111565742 B CN 111565742B
Authority
CN
China
Prior art keywords
cancer
axl
dose
leu
avb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880084046.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN111565742A (zh
Inventor
盖尔·麦金太尔
大卫·普罗哈斯卡
雷·塔比比亚扎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elavifer Biologics Inc
Original Assignee
Elavifer Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elavifer Biologics Inc filed Critical Elavifer Biologics Inc
Publication of CN111565742A publication Critical patent/CN111565742A/zh
Application granted granted Critical
Publication of CN111565742B publication Critical patent/CN111565742B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Marine Sciences & Fisheries (AREA)
CN201880084046.2A 2017-11-04 2018-11-05 使用axl诱骗受体治疗转移性癌症的方法 Active CN111565742B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762581671P 2017-11-04 2017-11-04
US62/581,671 2017-11-04
US201862618916P 2018-01-18 2018-01-18
US62/618,916 2018-01-18
US201862681944P 2018-06-07 2018-06-07
US62/681,944 2018-06-07
PCT/US2018/059218 WO2019090227A1 (en) 2017-11-04 2018-11-05 Methods of treating metastatic cancers using axl decoy receptors

Publications (2)

Publication Number Publication Date
CN111565742A CN111565742A (zh) 2020-08-21
CN111565742B true CN111565742B (zh) 2024-03-01

Family

ID=66333375

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880084046.2A Active CN111565742B (zh) 2017-11-04 2018-11-05 使用axl诱骗受体治疗转移性癌症的方法

Country Status (9)

Country Link
US (2) US20200289613A1 (https=)
EP (1) EP3703731A4 (https=)
JP (1) JP7286179B2 (https=)
KR (1) KR20200085307A (https=)
CN (1) CN111565742B (https=)
AU (2) AU2018359863A1 (https=)
CA (1) CA3080732A1 (https=)
MX (1) MX2020007130A (https=)
WO (1) WO2019090227A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4062914A4 (en) 2019-11-18 2024-01-17 Inxmed (Nanjing) Co., Ltd. USE OF AN FAK INHIBITOR IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF TUMORS PRESENTING AN NRAS MUTATION
WO2021141892A1 (en) * 2020-01-06 2021-07-15 Aravive Inc. Methods of treating clear cell renal carcinoma (ccrcc) using axl decoy receptors
EP4101453A4 (en) 2020-02-05 2024-05-15 Inxmed (Nanjing) Co., Ltd. COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS
GB202004189D0 (en) * 2020-03-23 2020-05-06 Bergenbio As Combination therapy
MX2023000810A (es) * 2020-07-19 2023-05-19 Aravive Inc Metodos de diagnostico para el cancer utilizando receptores señuelo axl.
TW202313044A (zh) * 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用
EP4398937A4 (en) * 2021-09-11 2025-07-09 Aravive Inc METHODS FOR TREATING LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA USING AXL DECOY RECEPTORS AS FIRST-LINE THERAPY
CN120418281A (zh) * 2022-12-29 2025-08-01 财团法人生物技术开发中心 靶向PD-L1和中和Gas6之融合蛋白及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103154020A (zh) * 2010-01-22 2013-06-12 小利兰·斯坦福大学托管委员会 抗转移疗法中axl信号传导的抑制
WO2016100738A2 (en) * 2014-12-18 2016-06-23 Ruga Corporation Antifibrotic activity of gas6 inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
DK2352763T4 (da) 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
PL2387395T3 (pl) * 2009-01-16 2015-03-31 Rigel Pharmaceuticals Inc Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2894539C (en) * 2012-12-14 2021-09-28 The Board Of Trustees Of The Leland Stanford Junior University Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
JP7042739B2 (ja) * 2015-08-20 2022-03-28 イプセン バイオファーム リミティド 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
US20180140679A1 (en) 2016-11-23 2018-05-24 The Board Of Trustees Of The Leland Stanford Junior University Modulation of axl receptor activity in combination with cytoreductive therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103154020A (zh) * 2010-01-22 2013-06-12 小利兰·斯坦福大学托管委员会 抗转移疗法中axl信号传导的抑制
WO2016100738A2 (en) * 2014-12-18 2016-06-23 Ruga Corporation Antifibrotic activity of gas6 inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies;Mihalis S Kariolis et al.;J Clin Invest;第127卷(第127期);183-192 *
Mihalis S Kariolis et al..Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.J Clin Invest.2016,第127卷(第127期),183-192. *

Also Published As

Publication number Publication date
CN111565742A (zh) 2020-08-21
EP3703731A1 (en) 2020-09-09
RU2020116224A3 (https=) 2022-05-06
WO2019090227A1 (en) 2019-05-09
JP2021502334A (ja) 2021-01-28
KR20200085307A (ko) 2020-07-14
JP7286179B2 (ja) 2023-06-05
US20200289613A1 (en) 2020-09-17
CA3080732A1 (en) 2019-05-09
EP3703731A4 (en) 2021-07-21
AU2018359863A1 (en) 2020-07-02
RU2020116224A (ru) 2021-12-06
AU2025201654A1 (en) 2025-03-27
MX2020007130A (es) 2021-02-15
US20240009271A1 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
CN111565742B (zh) 使用axl诱骗受体治疗转移性癌症的方法
AU2019218271B2 (en) Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies
ES2951650T3 (es) Uso de un anticuerpo anti-PD-1 junto con un anticuerpo anti-CD30 en el tratamiento del linfoma
JP6591428B2 (ja) 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ
Hu et al. Trop2-targeted therapy in breast cancer
KR20220008316A (ko) Lag-3/pd-l1 이중특이적 항체의 투여를 위한 투여 요법
CN111201030A (zh) 通过阻断tim-3和其配体的相互作用治疗癌症
WO2017172678A1 (en) Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
KR20220157515A (ko) Liv1-adc와 화학요법제를 사용한 병용 요법
CN113939309A (zh) 使用sEphB4-HSA融合蛋白治疗癌症
KR20240082379A (ko) 암 치료 방법 및 이의 약제학적 조성물
US20250123284A1 (en) Diagnostic methods for cancer using ephrinb2 expression
US20230277631A1 (en) Diagnostic methods for cancer using axl decoy receptors
EP4543919A1 (en) Combination therapies
RU2785866C2 (ru) Способы лечения метастатических видов рака с использованием рецепторов-ловушек axl
HK40030449A (en) Methods of treating metastatic cancers using axl decoy receptors
WO2024052674A1 (en) Modified t-cells for use in the treatment of bladder cancer
HK40086849A (en) Anti-cd47 agent-based treatment of cd20-positive cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40030449

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant